In vivo targeted magnetic resonance imaging and visualized photodynamic therapy in deep-tissue cancers using folic acid-functionalized superparamagnetic-upconversion nanocomposites

Literature Information

Publication Date 2015-04-14
DOI 10.1039/C5NR01932J
Impact Factor 7.79
Authors

Lijia Luo, Yuanwei Pan, Song Luo, Aiguo Wu



Abstract

Multifunctional nanoprobes used in magnetic resonance imaging (MRI) and photodynamic therapy (PDT) also have potential applications in diagnosis and visualized therapy of cancers, and hence it is important to investigate the active-targeting ability and in vivo reliability of these nanoprobes. In this work, folic acid (FA)-targeted, photosensitizer (PS)-loaded Fe3O4@NaYF4:Yb/Er (FA-NPs-PS) nanocomposites were synthesized for in vivo T2-weighted MRI and visualized PDT of cancers by modeling MCF-7 tumor-bearing nude mice. By measuring the upconversion luminescence (UCL) and fluorescence emission spectra, the as-prepared FA-NPs-PS nanocomposites showed near-infrared (NIR)-triggered PDT performance due to the production of a singlet oxygen species. Moreover, by tracing PS fluorescence in MCF-7, HeLa cells and in MCF-7 tumors, the FA-targeted nanocomposites demonstrated good targeting ability both in vitro and in vivo. Under the irradiation of a 980 nm laser, the viabilities of MCF-7 and HeLa cells incubated with FA-NPs-PS nanocomposites could decrease to about 18.4% and 30.7%, respectively, and the inhibition of MCF-7 tumors could reach about 94.9%. The transverse MR relaxivity of 63.79 mM−1 s−1 (r2 value) and in vivo MR imaging of MCF-7 tumors indicated an excellent T2-weighted MR performance. This work demonstrated that FA-targeted MRI/PDT nanoprobes are effective for in vivo diagnosis and visualized therapy of breast cancers.

Source Journal

Nanoscale

Nanoscale
CiteScore: 12.1
Self-citation Rate: 5.2%
Articles per Year: 1681

Nanoscale is a high-impact international journal, publishing high-quality research across nanoscience and nanotechnology. Nanoscale publishes a full mix of research articles on experimental and theoretical work, including reviews, communications, and full papers. Highly interdisciplinary, Nanoscale appeals to scientists, researchers and professionals interested in nanoscience and nanotechnology, quantum materials and quantum technology, including the areas of physics, chemistry, biology, medicine, materials, energy/environment, information technology, detection science, healthcare and drug discovery, and electronics. For publication in Nanoscale, papers must report high-quality reproducible new work that will be of significant general interest to the journal's wide international readership. Nanoscale is a collaborative venture between the Royal Society of Chemistry Publishing and a leading nanoscience research centre, the National Center for Nanoscience and Technology (NCNST) in Beijing, China. image block The journal publishes weekly issues, complementing and building on the nano content already published across the Royal Society of Chemistry Publishing journal portfolio. Since its launch in late 2009, Nanoscale has established itself as a platform for high-quality, cross-community research that bridges the various disciplines involved with nanoscience and nanotechnology, publishing important research from leading international research groups.

Recommended Suppliers

ChinaShanghai Biosundrug Co., Ltd
ChinaZhejiang Changxing Innovation Ultrafine Powder Co., Ltd.
GermanyHAW Linings GmbH
El SalvadorComercio y Representaciones SA de CV (Coresa de CV)
ChinaDezhou Hao Tian Group
United StatesCETAC Technologies
United KingdomRedd&Whyte Limited
GermanySteinhaus GmbH
GermanyPMR Tech UG (haftungsbeschränkt)
ChinaJock Electronic Drain Valve Shanghai Sales Company
Disclaimer
This page provides academic journal information for reference and research purposes only. We are not affiliated with any journal publishers and do not handle publication submissions. For publication-related inquiries, please contact the respective journal publishers directly.
If you notice any inaccuracies in the information displayed, please contact us at [email protected]. We will promptly review and address your concerns.